DMPA and Hypertension: Evidence-Based Assessment
Depot medroxyprogesterone acetate (DMPA) does not typically cause clinically significant hypertension and is considered safe for use in women with controlled hypertension, though blood pressure monitoring remains prudent given mixed evidence on modest effects.
Blood Pressure Effects of DMPA
The evidence regarding DMPA and hypertension is reassuring overall, with important distinctions from combined hormonal contraceptives:
Progestin-Only Safety Profile
- DMPA is not associated with the blood pressure elevations seen with combined hormonal contraceptives that contain estrogen 1
- The major disadvantages of DMPA include menstrual irregularities, need for injections every 13 weeks, and potential weight gain—but hypertension is not listed among the primary concerns 2, 3
- Progestin-only methods like DMPA have no restrictions for use in women with controlled hypertension (blood pressure <160/100 mmHg) 1
Clinical Trial Evidence
Research findings show variable but generally minimal effects:
- A 1978 study of 24 women found that blood pressure actually decreased from 124.1/79.4 to 115.6/73.2 mmHg over three months of DMPA use 4
- A long-term study of 50 women using DMPA for 120 months showed no difference in blood pressure changes compared to IUD users 5
- However, one study in men receiving high-dose MPA for sex-offending behavior showed significant increases in systolic blood pressure independent of weight gain 6
Mechanistic Considerations
- MPA can bind to glucocorticoid receptors and stimulate sodium retention pathways, which theoretically could affect blood pressure 7
- Recent pharmacovigilance data identified "decrease in blood pressure" as an adverse event signal (not increase), though this requires further validation 8
Clinical Recommendations for Blood Pressure Monitoring
Pre-Initiation Assessment
- Measure baseline blood pressure before starting DMPA, as this is recommended practice for all hormonal contraceptives 1
- No routine blood pressure screening is required beyond standard clinical practice, as DMPA does not carry the same cardiovascular risks as combined hormonal contraceptives 9
Use in Hypertensive Women
DMPA is an appropriate choice for women with hypertension:
- There are no restrictions on DMPA use for women with controlled hypertension (BP <160/100 mmHg) 1
- The advantages of DMPA outweigh theoretical risks even in women with uncontrolled hypertension (BP ≥160/100 mmHg) 1
- DMPA is specifically recommended as a hormonal alternative when combined hormonal contraceptives are contraindicated due to hypertension 1
Monitoring Schedule
- Monitor blood pressure at routine follow-up visits (typically every 11-13 weeks when receiving injections) 3
- If hypertension develops, consider whether weight gain (a known DMPA side effect) may be contributing 2
- Unlike combined hormonal contraceptives, DMPA does not require intensive blood pressure monitoring 1
Important Clinical Distinctions
Contrast with Combined Hormonal Contraceptives
- Combined oral contraceptives containing ethinyl estradiol cause a small but detectable increase in blood pressure in many users 10, 11
- The Nurses' Health Study found combined oral contraceptives increased hypertension risk (RR 1.8) 10
- This risk does NOT apply to progestin-only methods like DMPA 1, 11
Contrast with Medroxyprogesterone in Hormone Replacement Therapy
- Conjugated equine estrogens plus medroxyprogesterone acetate in postmenopausal women increased incident hypertension by 18% 12
- This effect was attributed to the estrogen component, not the progestin 12
- Postmenopausal hormone therapy data should not be extrapolated to contraceptive-dose DMPA in reproductive-aged women
Common Pitfalls to Avoid
- Do not withhold DMPA due to hypertension concerns—it is one of the safest hormonal options for hypertensive women 1
- Do not confuse DMPA with combined hormonal contraceptives—the blood pressure effects are fundamentally different 1, 11
- Do not attribute all blood pressure changes to DMPA—consider weight gain, which affects 21% of early users significantly 2
- Do not require extensive cardiovascular screening before DMPA initiation—baseline blood pressure measurement is sufficient 9